0001104659-19-015619.txt : 20190318 0001104659-19-015619.hdr.sgml : 20190318 20190318164028 ACCESSION NUMBER: 0001104659-19-015619 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190314 FILED AS OF DATE: 20190318 DATE AS OF CHANGE: 20190318 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Malik Usama CENTRAL INDEX KEY: 0001737803 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12104 FILM NUMBER: 19688756 MAIL ADDRESS: STREET 1: 300 THE AMERICAN WAY CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOMEDICS INC CENTRAL INDEX KEY: 0000722830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 611009366 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 AMERICAN RD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 BUSINESS PHONE: 9736058200 MAIL ADDRESS: STREET 1: 300 AMERICAN ROAD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 4 1 a4.xml 4 X0306 4 2019-03-14 0 0000722830 IMMUNOMEDICS INC IMMU 0001737803 Malik Usama C/O IMMUNOMEDICS, INC. 300 THE AMERICAN ROAD MORRIS PLAINS NJ 07950 0 1 0 0 Chief Financial & Business OFF Stock Option (right to buy) 17.94 2019-03-14 4 A 0 51320 0 A 2026-03-14 Common Stock, par value $0.01 per share 51320 51320 D Stock Option (right to buy) 17.94 2019-03-14 4 A 0 25660 0 A 2026-03-14 Common Stock, par value $0.01 per share 25660 25660 D The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan (the "Plan"). The stock options vest 25% on the first anniversary of the date of grant, and in 6.25% in equal quarterly installments thereafter. The reporting person was granted stock options pursuant to the Plan. The stock options vest (i) 50% upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act, and (ii) 50% on the second anniversary of the date of grant. /s/ Usama Malik 2019-03-18